Renal Cell Carcinoma
Predictive biomarkers for RCC urgently needed, difficult to uncover

With new targeted and immune-based treatments coming out for renal cell carcinoma, predictive biomarkers are needed more than ever. The many different tumor entities of RCC, their genetic and mutational alterations and different clinical behaviors all contribute to a complex disease that requires personalized treatment.
Nivolumab-ipilimumab combination confers durable responses in renal cell carcinoma
Pembrolizumab plus axitinib prolongs survival in advanced renal cell carcinoma
It’s a puzzlement
Novartis, TScan Therapeutics partner on cell therapies for solid tumors
Fotivda, Imfinzi combination trial for liver cancer begins enrollment
HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma
Targeted therapies linked to modest survival benefit for elderly patients with renal cell carcinoma
Strategies for managing older patients with renal cell carcinoma and comorbidities
More than half of patients diagnosed with renal cell carcinoma are at least 65 years old, and the median age at diagnosis is 64. Although increased life expectancies in general and prolonged survival times as a result of targeted therapies deserve optimism, elderly patients with renal cell carcinoma also bring unique clinical challenges. Beyond medical factors, social, psychological and financial elements also influence treatment practicalities and outcomes.